When one analyst is positive about an ASX share, that's interesting. When multiple experts rate a business as a buy, it could be a great time to invest (if they're right).
Share prices are always changing, so the available opportunities can change month to month. When we look across the ASX share market, the following two businesses are among the most widely backed.
Image source: Getty Images
Integral Diagnostics Ltd (ASX: IDX)
Integral Diagnostics describes itself as a leading provider of medical imaging services across Australia and New Zealand.
According to the Commsec collation of analyst opinions, there are currently 12 buy ratings on the business, with just one hold and one sell.
We should also look at the price target of the business, which tells us what analysts think the share price will do over the next 12 months. A price target is just an estimate though, not a guarantee of what's going to happen.
According to CMC Invest, of three analyst price targets issued within the last three months, the average price target is $3.19. That implies a possible rise of 53% over the next year, if the analysts are right.
The company's latest result saw plenty of growth following the merger with Capitol Health, with enhanced operational scale and a broader network, combined with synergies.
The company reported organic revenue growth of 7.4% from all sources in Australia. Total revenue grew 55.6%, operating profit (EBITDA) rose 75.6% and operating net profit grew 154.6% to $22.3 million. Operating earnings per share (EPS) rose by 66.2% to 5.9 cents.
This growth enabled the ASX share to hike its interim dividend per share by 32% to 3.3 cents.
TechnologyOne Ltd (ASX: TNE)
TechnologyOne is another ASX share with significant backing by expert analysts. The global enterprise resource planning (ERP) software business currently has 13 buy ratings on the business, according to CommSec.
It has clients across a range of industries including businesses, local councils, government organisations and universities.
According to CMC Invest, of eight recent ratings by analysts within the last three months, the average price target is $31.81. That implies a possible rise of around 6% within the next year.
The business expects to grow its profit at a significant pace during the 2026 financial year.
It expects to grow its FY26 annual recurring revenue (ARR) by between 16% to 18%, while its profit growth is expected to be between 18% to 20%.
If profit keeps growing in the high-teens year after year then it's on track for a very pleasing future, in my opinion (and according to broker analysts too).
